NCT04220411View on ClinicalTrials.gov

A Study for AR100DP1 in Mild to Moderate Atopic Dermatitis (AD)

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

December 8, 2020

Primary Completion Date

December 29, 2021

Study Completion Date

June 13, 2022

Conditions
Dermatitis, Atopic
Interventions
DRUG

AR100DP1

topical ointment

Trial Locations (1)

Unknown

Arjil Pharmaceuticals LLC., Hsinchu

Sponsors
All Listed Sponsors
lead

Arjil Pharmaceuticals LLC

INDUSTRY

NCT04220411 - A Study for AR100DP1 in Mild to Moderate Atopic Dermatitis (AD) | Biotech Hunter | Biotech Hunter